Patents Assigned to JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.
  • Patent number: 11643405
    Abstract: The invention discloses compounds for treatment or prevention of liver diseases. The compounds are compounds represented by a formula (I) or (II), optical isomers or pharmaceutically acceptable salts of the compounds. The compounds and optical isomers or pharmaceutically acceptable salts of the compounds can be applied to preparation of drugs for treatment or prevention of liver diseases.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: May 9, 2023
    Assignee: JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.
    Inventors: Dongfang Shi, Changjin Fu, Xi Cheng, Weiwei Gong, Jie Gu, Pengfei Li, Min Zhang, Yan Yang, Wenqing Jin
  • Patent number: 11597725
    Abstract: The present invention belongs to the field of medicinal chemistry. Specifically disclosed is a class of URAT1 inhibitors for promoting uric acid excretion, which are compounds as represented by the structure of formula (I) or pharmaceutically acceptable salts thereof. Experiments show that the compounds provided by the present invention have a very good inhibitory effect on the transport of uric acid by hURAT1 in HEK293 transfected cells, and that such compounds have a good application prospect in the treatment of hyperuricemia or gout.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: March 7, 2023
    Assignee: JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.
    Inventors: Dongfang Shi, Jianghua Zhu, Jie Gu, Xi Cheng, Yan Yang, He Zhou, Pengfei Li, Fan Wu
  • Patent number: 10875865
    Abstract: Disclosed are a class of URAT1 inhibitor compounds and the use of such compounds. These compounds are compounds represented by the structure of formula (I) or pharmaceutically acceptable salts thereof. Experiments show that the compounds provided by the present invention have a very good inhibitory effect on hURAT1-transported uric acid in HEK293 transfected cells, and show that such compounds have a good potential for application in the treatment of hyperuricemia or gout.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: December 29, 2020
    Assignee: JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.
    Inventors: Dongfang Shi, Changjin Fu, Xi Cheng, Jianghua Zhu, Jie Gu
  • Patent number: 10399971
    Abstract: The invention discloses a class of compounds for treating or preventing hyperuricemia or gout, which is a compound shown in general formula (I) or a pharmaceutically acceptable salt. These compounds and their pharmaceutically acceptable salts in the invention are useful for the promotion of uric acid excretion to treat or prevent hyperuricemia or gout.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: September 3, 2019
    Assignee: JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.
    Inventors: Dongfang Shi, Changjin Fu, Xi Cheng, Jianghua Zhu, Jie Wen, Jie Gu
  • Patent number: 10005744
    Abstract: It discloses compounds for the treatment and prevention of breast cancer, which are specifically 2-phenyl benzoselenazole compounds, pharmaceutically acceptable salts thereof and prodrugs thereof. The present invention further discloses pharmaceutical compositions containing the compounds and applications of the compounds in preparing medicines for the treatment and prevention of breast cancer in mammals. The compounds of the present invention can effectively inhibit or reduce the growth or proliferation of breast cancer cells in mammals, with no inhibition effect on the growth of part of the tested cell lines except for the breast cancer cell lines, and are highly selective.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: June 26, 2018
    Assignee: JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.
    Inventors: Dongfang Shi, Changjin Fu, Xi Cheng, Jianghua Zhu
  • Patent number: 9802907
    Abstract: A 2-aryl selenazole compound and a pharmaceutical composition are disclosed, wherein the 2-aryl selenazole compound is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The 2-aryl selenazole compound has the activity of inhibiting xanthine oxidase. The compound or a pharmaceutically acceptable salt thereof can be applied in terms of preparing a drug used for prevention or treatment of hyperuricemia, gout, diabetic nephropathy, an inflammatory disease or a neurological disease.
    Type: Grant
    Filed: November 24, 2013
    Date of Patent: October 31, 2017
    Assignee: JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD.
    Inventors: Dongfang Shi, Changjin Fu, Jie Wu, Jun Liu